Systematic validation of disease models for pharmacoeconomic evaluations

Journal of Evaluation in Clinical Practice

Volumn 5, Issue 3, 1999, Pages 283-295

  Sendi, Peter P ^a,e   Craig, Bruce A ^b   Pfluger, Dominik ^c   Gafni, Amiram ^d   Bucher, Heiner C ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b PURDUE UNIVERSITY   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

^d MCMASTER UNIVERSITY   (Canada)

^e KANTONSSPITAL BASEL   (Switzerland)

Author keywords

AIDS epidemiology; AIDS related opportunistic infections; Cost benefit analysis; Markov chains; Mycobacterium avium infection; Probability

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN;

ARTICLE; CANCER SURVIVAL; COMPUTER MODEL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE MODEL; DRUG EFFICACY; HEALTH CARE POLICY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MYCOBACTERIOSIS; PRIORITY JOURNAL; RISK; SWITZERLAND;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CLARITHROMYCIN; COMPUTER SIMULATION; DISEASE PROGRESSION; ECONOMICS, PHARMACEUTICAL; HIV INFECTIONS; HUMANS; MARKOV CHAINS; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; PROBABILITY; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SWITZERLAND;

EID: 0032838813     PISSN: 13561294     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2753.1999.00174.x     Document Type: Article

References (30)

1. Arzneimittel-Kompendium der Schweiz (1997) Documed AG, Basel, Switzerland, available from URL: http:\\195.65.20.225.
2. Beck J.R., Katta M.W. & Miles B.J. (1994) A critique of the decision analysis for clinically localized prostate cancer. Journal of Urology 152, 1894-1899.
3. Briggs A. & Sculpher M. (1998) An Introduction to Markov Modelling for Economic Evaluation. Pharmacoeconomics 13, 397-409.
4. Buxton M.J., Drummond M.F., Van Hout B.A., Prince R.L., Sheldon T.A., Szucs T. & Vray M. (1997) Modelling in economic evaluation: an unavoidable fact of life. Health Economics 6, 217-227.
5. Centers for Disease Control and Prevention (1992) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report 41, 1-20.
6. Craig B.A. & Newton M.A. (1997) Modeling the history of diabetic retinopathy. In: Case Studies in Bayesian Statistics III (ed. C. Gatsonis), pp. 305-323. Springer-Verlag, New York.
7. Craig B.A. & Sendi P.P. (1998) Estimating the transition matrix of a homogenous Markov chain. Technical Report # 98-12. Department of Statistics, Purdue University, West Lafayette, Indiana, USA.
8. Egger M., Hirschel B., Francioli P., Sudre Ph., Wirz M., Flepp M., Rickenbach M., Malinverni R., Vernazza P. & Battegay M. (1997) Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicenter study. British Medical Journal 315, 1194-1199.
9. Fleming C., Wasson J.H., Albertsen P.C., Barry M.J. & Wennberg J.E. (1993) A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. Journal of the American Medical Association 269, 2650-2658.
10. Freedberg K.A., Cohen C.J. & Barber T.W. (1997) Prophylaxis for disseminated Mycobacterium avium complex (MAC) infection in patients with AIDS: a cost-effectiveness analysis. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 15, 275-282.
11. Freedberg K.A., Scharfstein J.A., Seag G.R., 3rd Losina E., Weinstein M.C., Craven D.E. & Paltiel D.A. (1998) The cost-effectiveness of preventing AIDS-related opportunistic infections. Journal of the American Medical Association 279, 130-136.
12. Helfand M. (1998) Book review: Cost-effectiveness in health and medicine. Medical Decision Making 18, 240-243.
13. Horsburgh C.R. Jr (1991) Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. New England Journal of Medicine 324, 1332-1338.
14. Kleijnen J.P.C. (1995) Verification and validation of simulation models. European Journal of Operational Research 82, 145-162.
15. Krahn M.D., Naglie G., Naimark D., Redelmeier D.A. & Detsky A.S. (1997) Primer on medical decision analysis: Part 4 - Analyzing the model and interpreting the results. Medical Decision Making 17, 142-151.
16. Laurichesse H.A., Mortimer J., Evans B.G. & Farrington C.P. (1998) Pre-AIDS mortality in HIV-infected individuals in England, Wales and Northern Ireland. 1982-96. AIDS 12, 651-658.
17. Ledergerber B., von Overbeck J., Egger M. & Luthy R. (1994) The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. Sozial- und Praventivmedizin 39, 387-394.
18. Low N., Pfluger D. & Egger M. (1997) Disseminated Mycobacterium avium complex disease in the Swiss HIV Cohort Study: increasing incidence, unchanged prognosis. AIDS 11, 1165-1171.
19. Luce B.R. (1998) Pharmacoeconomics and managed care: methodologic and policy issues. Medical Decision Making 18, S4-S11.
20. Mandelblatt J.S., Fryback D.G., Weinstein M.C., Russell M.R. & Hadorn D.C. (1996) Assessing the effectiveness of health interventions. In: Cost-Effectiveness in Health and Medicine (eds M.R. Gold, J.E. Siegel, L.B. Russell & M.C. Weinstein), pp. 135-175. Oxford University Press, New York.
21. Miller D.K. & Homan S.M. (1994) Determining transition probabilities: confusion and suggestions. Medical Decision Making 14, 52-58.
22. Moore R.D. & Chaisson R.E. (1997) Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 16, 15-21.
23. Nightingale S.D., Cameron D.W., Gordin P.M., Sullam P.M., Cohn D.L., Chaisson R.E., Eron L.J., Sparti P.D., Bihari B. & Kaufman D.L. (1993) Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. New England Journal of Medicine 329, 828-833.
24. Oldfield E.C., Dickinson G., Chung M.R., Wallace M.R., Craig D.B., Fessel W.J., Joyce M.P., McKee K.T., Melcher G., Wagner K.F., Williams W.J., Zajdowicz M., Heifeits L., Dunne M.W., Bermann J. & the 066-155 Study Investigators (1996) Once weekly azithromycin for the prevention of Mycobacterium avium complex (MAC) infection in AIDS patients. 3rd Conference on Retroviruses and Opportunistic Infections, Washington DC, USA.
25. Paltiel A.D., Scharfstein J.A., Seage G.R. 3rd, Losina E., Goldie S.J., Weinstein M.C., Craven D.E. & Freedberg K.A. (1998) A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection. Medical Decision Making 18, S93-S105.
26. Pierce M., Crampto S., Henry D., Heifets L., LaMarca A., Montecalvo M., Wormser G.P., Jablonowski H., Jemsek J., Cynamon M., Yangco B.G., Notario G. & Craft J.C. (1996) A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. New England Journal of Medicine 335, 384-391.
27. Rose D.N. & Sacks H.S. (1997) Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing. AIDS 11, 883-887.
28. Sendi P.P., Bucher H.C., Craig B.A., Pfluger D. & Battegay M. (1999) Estimating AIDS-free survival in a severely immunosuppressed asymptomatic HIV-infected population in the era of antiretroviral triple combination therapy. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, in press.
29. Sonnenberg F.A. & Beck J.R. (1993) Markov models in medical decision making: a practical guide. Medical Decision Making 13, 322-338.
30. Sonnenberg F.A., Roberts M.S., Tsevat J., Wong J.B., Barry M. & Kent D.L. (1994) Toward a peer review process for medical decision analysis models. Medical Care 32, JS52-JS64.